NCT07209449View on ClinicalTrials.gov

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2028

Conditions
Endometrial Cancer
Interventions
DRUG

Abemaciclib

orally only in the evening

DRUG

Elacestrant

orally once daily in the morning

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau, Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack, Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth, Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT07209449 - A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | Biotech Hunter | Biotech Hunter